Premium
Why as a Medicinal Chemist I Am Not Optimistic about the Possibility of Finding, in a Reasonable Timeframe, Small‐Molecule Drugs Capable of Curing the Evolution of Alzheimer’s Disease
Author(s) -
Kraus JeanLouis
Publication year - 2012
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201100431
Subject(s) - chemist , disease , dementia , neuroscience , cognition , brain function , cognitive science , medicine , psychology , nanotechnology , chemistry , materials science , organic chemistry , pathology
Herein I explain why I feel that new and effective Alzheimer′s disease (AD) drugs cannot emerge from current developed concepts such as the amyloid pathway, or acetylcholinesterase inhibitors. The discovery of new therapeutic approaches first requires an understanding of the intimate structure of brain matter, where memory and cognition are located, and how aging alters its structure and function. Only by joining the expertise of quantum physicists and physical chemists with that of medicinal chemists, pharmacologists, biologists and medical doctors can new AD research orientations emerge.